This contract is known to be for the settlement of the US International Trade Commission (ITC) lawsuit against the sale of bulletins, and this is a procedure that was carried out without prior consent from Daewoong Pharmaceutical.
Ebolus’ agreement is interpreted as a decision based on management judgment to avoid disruption of the company’s business activities as ITC issued a 21-month import ban on the bulletin.
Daewoong Pharmaceutical said, “It is analyzed that AbbVie and Medytox have urgently agreed with Ebolus, as the application for emergency provisional injunction against ITC’s 21-month import ban was cited and the appeal was underway, which created a case of lawsuit against them.” .
He added, “Currently, I filed an appeal to the US Federal Circuit Court of Appeals (CAFC) through expedited procedures, and I am confident that all of Medytox’s claims will be found false in the appeals court. So there was no reason to agree with AbbVie and Medytox.” “However, it is regrettable that the opportunity to correct errors in ITC decisions has been eliminated according to this agreement.”
With a third-party agreement, Daewoong Pharmaceutical evaluated that the risks in its business in the US were completely resolved and the foundation for Nabota sales was laid.
Daewoong said, “Based on Nabota’s advanced quality and technology, we plan to accelerate our global market penetration with Evolus. Based on Nabota’s advanced quality and technology, we plan to accelerate our global market penetration with Evolus. “I said.
“We will continue our efforts to clarify the truth about the numerous unfounded claims of Meditox that have been revealed so far,” he said. “We will take the lead in developing innovative technologies and improving quality in order to restore the public confidence of K-Bio, which was depressed by Meditox. In addition, he emphasized, “We will do our best to improve the convenience of the people by providing safe and high quality medicines.”